Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor type 2 receptor (HER2), resulting in a poor prognosis, since these cell types do not respond to conventional receptor-targeted therapies [2]. Here, PGR is linked to triple-negative breast carcinoma.